Correction to

Other Title
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan (Targeted Oncology, (2022), 17, 3, (295-306), 10.1007/s11523-022-00878-x)
Journal
Targeted Oncology
Date Issued
2023-01-01
Author(s)
DOI
URI
Abstract
The article The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non- Small Cell Lung Cancer in Taiwan, written by Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen and Gee-Chen Chang, was originally published electronically in SpringerLink on 23 April 2022 without open access.
Type
journal article